Skip to main content
TISSUE REPAIR LTD logo

TISSUE REPAIR LTD — Investor Relations & Filings

Ticker · TRP ISIN · AU0000180887 ASX Professional, scientific and technical activities
Open in API
Filings indexed 139 across all filing types
Latest filing 2021-11-16 Governance Information
Country AU Australia
Listing ASX TRP

About TISSUE REPAIR LTD

https://tissuerepair.com.au/

Tissue Repair Ltd is a clinical-stage biopharmaceutical company focused on the development of advanced wound healing and skin repair agents. The company’s core technology centers on Glucoprime, a proprietary yeast-derived beta-glucan designed to stimulate the innate immune system and accelerate the body's natural healing processes. Its lead candidate, TR-987, is being developed for the treatment of chronic wounds, such as venous leg ulcers, and for use in post-procedural recovery following aesthetic treatments. By targeting the inflammatory phase of wound healing, the technology aims to improve clinical outcomes and reduce recovery times. The company focuses on addressing unmet needs in both the medical wound care and cosmetic dermatology markets through its specialized biological platform.

Recent filings

Filing Released Lang Actions
Securities Trading Policy 10 pages 214.6KB
Governance Information Classification · 95% confidence The document is a detailed policy on securities trading, insider trading prohibitions, closed periods for trading, and clearance processes for key management personnel of Tissue Repair Ltd, a company listed on the Australian Securities Exchange (ASX). It discusses compliance with insider trading laws, trading restrictions, and governance related to securities trading by directors, officers, and employees. There is no financial data, earnings information, audit results, or report publication mentioned. The content is focused on governance and compliance policies related to securities trading and insider trading, which aligns with governance information about internal rules and board practices. Therefore, the document fits best under Governance Information (CGR).
2021-11-16 English
Distribution Schedule 1 page 66.9KB
Major Shareholding Notification Classification · 95% confidence The document is titled 'Holdings Range Report' for Tissue Repair Ltd and provides a detailed breakdown of shareholding ranges, number of holders, total units, and percentage of issued share capital as of a specific date (16-Nov-2021). It is a summary report of share ownership distribution rather than a narrative or financial performance report. The document length is short (1567 characters) and contains no financial statements, management discussion, or regulatory certifications. It does not announce voting results, changes in management, or capital structure changes. The content fits best with a Major Shareholding Notification or similar category that reports on share ownership levels. Given the detailed shareholding ranges and percentages, the most appropriate classification is Major Shareholding Notification (MRQ).
2021-11-16 English
Top 20 Shareholders 2 pages 74.0KB
Major Shareholding Notification Classification · 95% confidence The document is titled 'Top Holders Grouped Report' and lists the top shareholders of Tissue Repair Ltd as of a specific date (16-Nov-2021). It provides detailed shareholding percentages and names of major shareholders. There is no indication of financial statements, management discussion, or regulatory announcements. The content is a notification of significant share ownership levels, which aligns with the definition of Major Shareholding Notification (MRQ). The document length is 3227 characters, which is consistent with a detailed shareholding report rather than a brief announcement or a full financial report.
2021-11-16 English
Pre-quotation Disclosure 2 pages 236.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement related to the company's initial public offering (IPO) and pre-quotation disclosures. It details the completion of the share issue, the number of shares and options issued, corrections to previously disclosed option numbers, restricted securities, voluntary escrow arrangements, and the capital structure post-offer. The document is relatively short (3757 characters) and serves as a market announcement rather than a full financial report or prospectus. It does not contain comprehensive financial statements or detailed management discussion. Therefore, it is best classified as a Capital/Financing Update (CAP) since it provides updates on the company's fundraising and capital structure changes associated with the IPO.
2021-11-16 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.